SOURCE: Syneron Medical Ltd.

September 29, 2005 15:08 ET

Syneron Presentation at UBS Global Life Sciences Conference Rescheduled to 3:00pm ET

YOKNEAM, ISRAEL -- (MARKET WIRE) -- September 29, 2005 -- Syneron Medical Ltd. (NASDAQ: ELOS) announced a rescheduling of its presentation today at the UBS Global Life Sciences Conference in New York City. Syneron is now scheduled to present at 3:00 p.m. E.T.

The presentation will be broadcast live over the Internet and can be accessed directly on Please go to the Web site a few minutes early, as it may be necessary to download audio software to hear the presentation. An archived replay of the presentation will also be available approximately one hour following the live presentation on the Syneron website

About Syneron

Syneron Medical Ltd. (NASDAQ: ELOS) manufactures and distributes medical aesthetic devices that are powered by elôs, the combined-energy technology of bi-polar radio frequency and light. The company's innovative elôs technology provides the foundation for highly effective, safe and cost-effective systems that enable physicians to provide advanced solutions for a broad range of medical-aesthetic applications including hair removal, wrinkle reduction, rejuvenating the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. is located in Israel. Syneron has offices and distributors throughout the world, including North American Headquarters in Canada, European Headquarters in Germany, and Asia-Pacific Headquarters in Hong Kong, which provide sales, service and support. Additional information can be found at

Syneron, the Syneron logo and elôs are trademarks of Syneron Medical Ltd. and may be registered in certain jurisdictions. Elôs (Electro-Optical Synergy) is a proprietary technology of Syneron Medical. All other names are the property of their respective owners.

Contact Information

  • For more information, please contact
    Judith Kleinman
    VP Investor Relations
    tel: +972 4909 6282
    email: Email Contact